Peptide Hubs
PANCRAGEN 20 MG
CLASSIFICATION: ORGAN-SPECIFIC PEPTIDE
ACTIVE SUBSTANCE: PANCRAGEN
FORM: LYOPHILIZED POWDER (2 ML VIAL x 20 MG)
ACTIVE HALF-LIFE: APPROX. 6–8 HOURS
DOSAGE: 20–40 MG/WEEK (RESEARCH USE)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NONE
AROMATIZATION: NO
MANUFACTURER: PEPTIDE HUBS
Out of stock
Pancragen 20 mg – Peptide Hubs
Pancragen is an organ-specific peptide complex designed to support pancreatic health, insulin signaling, and beta-cell activity. Derived from natural cytomedin peptides targeting the pancreas, Pancragen may regulate gene expression, enhance tissue repair, and support glucose metabolism in research settings. Peptide Hubs provides Pancragen in a 20 mg lyophilized format suitable for advanced metabolic and endocrine research.
Mechanism of Action
Pancragen's mechanism focuses on restoring pancreatic tissue function at the molecular level. The short peptides in Pancragen bind to nuclear structures and modulate gene expression, potentially enhancing insulin production and protecting beta cells. This mechanism aligns with cytogenetic peptide research as discussed in this NIH article on peptide bioregulators.
Primary Research Applications
- Pancreatic regeneration and beta-cell support studies
- Insulin pathway modulation research
- Preclinical models of diabetes and metabolic syndrome
- Endocrine and glucose regulation studies
Pancragen is frequently combined with Semaglutide or MOTS-c in research focused on metabolic and glycemic regulation. For oxidative stress and mitochondrial protection, Humanin is a common stack. DNA integrity and cellular repair models may also include FOX04-DRI or L-Glutathione.
Suggested Experimental Use
- Dosage: 20–40 mg per week (e.g. 10 mg 2–4x/week)
- Administration: Subcutaneous injection in preclinical settings
- Duration: Typically 4–6 weeks in pancreas-focused protocols
Stacking Recommendations
- Semaglutide – GLP-1 pathway synergy
- Humanin – mitochondrial and beta-cell protection
- MOTS-c – metabolic resilience and energy balance
- L-Glutathione – antioxidant and DNA support
Legal Disclaimer
Pancragen is not approved by the FDA and is intended for research purposes only. No androgenic, estrogenic, or hepatotoxic effects have been reported in preclinical data. Proper storage and handling protocols should be followed as per institutional guidelines.
Frequently Asked Questions
What is Pancragen used for in research?
Pancragen is studied for its role in pancreatic tissue repair, insulin signaling, and beta-cell function support in models of metabolic dysfunction.
Does Pancragen affect insulin production?
Research suggests Pancragen may help support insulin gene expression and pancreatic beta-cell recovery, though it is not a replacement for insulin itself.
Can Pancragen be stacked with GLP-1 agonists?
Yes. It is often stacked with compounds like Semaglutide or MOTS-c in studies related to glucose homeostasis and insulin sensitivity.
Is Pancragen FDA approved?
No. Pancragen is not FDA-approved. It is intended for laboratory use only and is not sold for human or veterinary administration.
No reviews found
Please log in to write PANCRAGEN 20 MG review.